The pattern and dynamics of white matter alterations in Spinocerebellar ataxia type 1: A diffusion-weighted magnetic resonance imaging study

脊髓小脑性共济失调1型患者白质改变的模式和动态:一项弥散加权磁共振成像研究

阅读:2

Abstract

BACKGROUND: Spinocerebellar ataxia type 1 (SCA1) is a rare, neurodegenerative disease. Upcoming clinical disease-modifying trials require biomarkers sensitive to disease progression. This study aims to investigate diffusion MRI (dMRI) metrics as a possible outcome measure in such trials. METHODS: 46 participants (26 SCA1, 20 matched healthy controls (HC)) underwent 3 T MRI examination and clinical assessment of ataxia severity (SARA) at three timepoints over the duration of two years, including dMRI. Diffusion metrics (fractional anisotropy, mean diffusivity, radial diffusivity, axial diffusivity) were examined using tract-based spatial statistics (TBSS) and ROI-based extraction. Results were evaluated for change over time and relation to disease severity. RESULTS: Cerebellar white matter, in particular all cerebellar peduncles, showed significant (p < 0.001) differences between SCA1 and HC groups at baseline in all diffusion metrics. After two years, dynamics were only observed in the inferior cerebellar peduncle (ICP). However, a sub-group of early-stage disease patients (SARA ≤ 11) showed significant change in the corticospinal tract (CST) and pontine crossing tract (PCT), indicating stage-dependent dynamics. Cortical regions did not show cross-sectional differences between groups, but did change significantly in both anterior and posterior regions in the SCA1 group (p < 0.001). CONCLUSION: SCA1 patients showed significantly impaired white matter integrity in the cerebellar regions, when compared to HC. At the group level, diffusion metrics show dynamic effects in the ICP and in cortical regions. Patients in early disease stages furthermore show dynamic change in the CST and PCT. This indicates that white matter alterations follow a specific pattern throughout the disease and that measurements thereof are most useful in clinical trials targeting early disease stages.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。